Real-World data on vericiguat for heart failure in india
NCT ID NCT06632483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at medical records from over 600 Indian adults with chronic heart failure who were prescribed vericiguat between 2022 and 2023. Researchers want to see how the drug is used in routine care, how well it works, and what side effects occur. No new tests or visits are needed—only existing data is reviewed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Multiple Locations, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart failure drug puzzle: study aims to untangle polypharmacy risks
- Salt pills for heart failure? new study investigates
- Smartphone app may help heart failure patients get the right meds faster
- Which workout is best for heart failure? new study aims to find out
- Could a common steroid speed heart shock recovery?
- Smart alerts aim to cut heart failure hospital stays